No connection

Search Results

NXL vs SINT

NXL
Nexalin Technology, Inc.
BEARISH
Price
$0.51
Market Cap
$10.5M
Sector
Healthcare
AI Confidence
90%
SINT
Sintx Technologies, Inc.
BEARISH
Price
$2.69
Market Cap
$11.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
NXL
--
SINT
--
Forward P/E
NXL
-1.64
SINT
-1.53
P/B Ratio
NXL
2.61
SINT
3.64
P/S Ratio
NXL
34.73
SINT
10.89
EV/EBITDA
NXL
-0.81
SINT
-1.0

Profitability

Gross Margin
NXL
79.65%
SINT
45.28%
Operating Margin
NXL
-1403.86%
SINT
-787.59%
Profit Margin
NXL
0.0%
SINT
0.0%
ROE
NXL
-221.5%
SINT
-303.8%
ROA
NXL
-118.41%
SINT
-69.8%

Growth

Revenue Growth
NXL
532.5%
SINT
-46.5%
Earnings Growth
NXL
--
SINT
--

Financial Health

Debt/Equity
NXL
--
SINT
1.11
Current Ratio
NXL
4.84
SINT
1.51
Quick Ratio
NXL
4.29
SINT
1.16

Dividends

Dividend Yield
NXL
--
SINT
--
Payout Ratio
NXL
0.0%
SINT
0.0%

AI Verdict

NXL BEARISH

NXL exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company shows explosive year-over-year revenue growth of 532.50%, this is completely offset by a catastrophic operating margin of -1403.86% and negative ROE of -221.50%. The stock is currently trading at an exorbitant Price/Sales ratio of 34.73, which is unsustainable given the lack of profitability. Despite a recent short-term price bounce and a single analyst's 'buy' rating, the underlying deterministic data suggests a high risk of capital impairment.

Strengths
Exceptional YoY revenue growth (532.50%)
Strong gross margins (79.65%) indicating product value
Healthy short-term liquidity (Current Ratio 4.84)
Risks
Extreme operational inefficiency (Operating Margin -1403.86%)
Critical financial health failure (Piotroski F-Score 1/9)
Severe valuation disconnect (P/S Ratio 34.73)
SINT BEARISH

SINT exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -787.59%. The company is experiencing a collapse in its top line with YoY revenue growth at -46.50% and a consistent track record of missing earnings estimates (0/4 beats in the last year). Despite a 'Strong Buy' analyst consensus and a target price of $10.17, the fundamental data suggests a company in a death spiral with a 5-year price change of -100%. The disconnect between analyst optimism and the deterministic health scores indicates extreme speculative risk.

Strengths
Positive Gross Margin (45.28%) suggesting some product-level viability
Current Ratio of 1.51 provides a minimal short-term liquidity buffer
Quick Ratio of 1.16 indicates ability to cover immediate liabilities
Risks
Severe revenue contraction (-46.50% YoY)
Extreme operational inefficiency (Operating Margin -787.59%)
Massive equity erosion (ROE -303.80%)

Compare Another Pair

NXL vs SINT: Head-to-Head Comparison

This page compares Nexalin Technology, Inc. (NXL) and Sintx Technologies, Inc. (SINT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile